EUVIMEDSkopri EUVIMED
Open access · CC BY 4.0

mRNA PROTACs: engineering PROTACs for high‐efficiency targeted protein degradation

Xiaoqi Xue iD, Chen Zhang, Xiaolin Li, Junqiao Wang, Haowei Zhang, Ying Feng, Naihan Xu, Hongyan Li, Chunyan Tan iD, Yuyang Jiang, Ying Tan

MedComm · 2024-02 · 5 (2)

DOI: 10.1002/mco2.478 ↗

At a glance

Journal article in MedComm, published online on 2024-02-19. Written by Xiaoqi Xue and 10 co-authors. Institution: State Key Laboratory of Chemical Oncogenomics Institute of Biopharmaceutical and Health Engineering Shenzhen International Graduate School, Tsinghua …. Cited 9 times so far (Crossref); 36 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Basic Research Program of China.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Proteolysis‐targeting chimeras (PROTACs) are essential bifunctional molecules that target proteins of interest (POIs) for degradation by cellular ubiquitination machinery. Despite significant progress made in understanding PROTACs' functions, their therapeutic potential remains largely untapped. As a result of the success of highly flexible, scalable, and low‐cost mRNA therapies, as well as the advantages of the first generation of peptide PROTACs (p‐PROTACs), we present for the first time an engineering mRNA PROTACs (m‐PROTACs) strategy. This design combines von Hippel–Lindau (VHL) recruiting peptide encoding mRNA and POI‐binding peptide encoding mRNA to form m‐PROTAC and promote cellular POI degradation. We then performed proof‐of‐concept experiments using two m‐PROTACs targeting two cancer‐related proteins, estrogen receptor alpha and B‐cell lymphoma‐extra large protein. Our results demonstrated that m‐PROTACs could successfully degrade the POIs in different cell lines and more effectively inhibit cell proliferation than the traditional p‐PROTACs. Moreover, the in vivo experiment demonstrated that m‐PROTAC led to significant tumor regression in the 4T1 mouse xenograft model. This finding highlights the enormous potential of m‐PROTAC as a promising approach for targeted protein degradation therapy.

Subjects

Author keywords

Targeted protein degradation (TPD)in vitro transcribed mRNA (IVT‐mRNA)mRNApeptide proteolysis‐argeting chimerasproteolysis‐argeting chimeras (PROTAC)

Authors and institutions

  • State Key Laboratory of Chemical Oncogenomics Institute of Biopharmaceutical and Health Engineering Shenzhen International Graduate School, Tsinghua University Shenzhen China.
  • School of Food and Drug Shenzhen Polytechnic University Shenzhen China.
  • Shenzhen NeoCura Biotechnology Co., Ltd. Shenzhen China.

ORCID profiles: Xiaoqi Xue, Chunyan Tan

Funding

  • National Basic Research Program of China

Cite

APA

Xue, X., Zhang, C., Li, X., Wang, J., Zhang, H., Feng, Y., Xu, N., Li, H., Tan, C., Jiang, Y., & Tan, Y. (2024). mRNA PROTACs: engineering PROTACs for high‐efficiency targeted protein degradation. MedComm, 5(2). https://doi.org/10.1002/mco2.478

Vancouver

Xue X, Zhang C, Li X, Wang J, Zhang H, Feng Y, et al. mRNA PROTACs: engineering PROTACs for high‐efficiency targeted protein degradation. MedComm. 2024;5(2). doi:10.1002/mco2.478

BibTeX
@article{Xue2024,
  author = {Xue, Xiaoqi and Zhang, Chen and Li, Xiaolin and Wang, Junqiao and Zhang, Haowei and Feng, Ying and Xu, Naihan and Li, Hongyan and Tan, Chunyan and Jiang, Yuyang and Tan, Ying},
  title = {mRNA PROTACs: engineering PROTACs for high‐efficiency targeted protein degradation},
  journal = {MedComm},
  year = {2024},
  volume = {5},
  number = {2},
  doi = {10.1002/mco2.478}
}
Start for free →